Last update May 29, 2022
Limited compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Cidofovir in other languages or writings:
Cidofovir belongs to these groups or families:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | < 10 | % |
Molecular weight | 279 | daltons |
Protein Binding | 6 | % |
VD | 0.53 | l/Kg |
pKa | 1.26 | - |
T½ | 2.4 - 3.2 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by La Liga de la Leche, España of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Cidofovir is a nucleoside analog active against herpesviruses. It is used to treat CMV retinitis in AIDS patients and is being investigated for ocular herpes simplex, smallpox, and other viral infections. Intravenous administration. Off label it is used topically to treat skin lesions such as papillomas, warts and other lesions caused by the human papillomavirus (HPV).
Since the last update we have not found published data on its excretion in breastmilk.
Its low protein binding and low molecular weight would facilitate excretion in breast milk; its high volume of distribution would make it difficult.
Its very low oral bioavailability makes it difficult for it to pass to the infant plasma from ingested breast milk, except in premature infants and in the immediate neonatal period in which there may be greater intestinal permeability.
Side effects can be severe and frequent; it has significant renal toxicity and is a possible carcinogen. (AEMPS 2016)
It has been withdrawn from the market in most countries.
TOPICAL USE:
Local absorption across the epithelium is negligible and plasma concentrations are very low (Bossens 2018), so topical use of cidofovir might be acceptable during breastfeeding.
See below the information of this related product: